TrialHaemophilia : the official journal of the World Federation of Hemophilia2022

Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis.

Maria Elisa Mancuso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.